K. P. Golay

发表

Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients

J. Fellay, A. Telenti, T. Buclin, 2005, European Journal of Clinical Pharmacology.

Oral administration of a low dose of midazolam (75 μg) as an in vivo probe for CYP3A activity

A. Telenti, T. Buclin, C. Eap, 2004, European Journal of Clinical Pharmacology.

CYP3A activity measured by the midazolam test is not related to 3435 C >T polymorphism in the multiple drug resistance transporter gene.

J. Fellay, A. Telenti, T. Buclin, 2004, Pharmacogenetics.

Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects

A. Telenti, T. Buclin, C. Eap, 2004, European Journal of Clinical Pharmacology.

Methadone Blood Concentrations Are Decreased by the Administration of Abacavir Plus Amprenavir

G. Pantaleo, C. Eap, P. Baumann, 2001, Therapeutic drug monitoring.

Multicenter Study on the Clinical Effectiveness, Pharmacokinetics, and Pharmacogenetics of Mirtazapine in Depression

C. Eap, P. Vandel, H. Hilleret, 2012, Journal of clinical psychopharmacology.

Increase of Oral Methadone Dose in Methadone Injecting Patients

C. Eap, K. P. Golay, C. Uehlinger, 2003, Journal of addictive diseases.

Paroxetine Increases Steady-State Concentrations of (R)-Methadone in CYP2D6 Extensive but Not Poor Metabolizers

C. Eap, M. Kosel, U. von Bardeleben, 2002, Journal of clinical psychopharmacology.

Cytochrome P4503A4 metabolic activity, methadone blood concentrations, and methadone doses.

C. Eap, P. Baumann, S. Maxwell, 2003, Drug and alcohol dependence.

Methadone maintenance treatment and St. John's Wort - a case report.

P. Baumann, C. Eap, R. Oppliger, 2003, Pharmacopsychiatry.

Steady-State Concentrations of Mirtazapine, N-Desmethylmirtazapine, 8-Hydroxymirtazapine and their Enantiomers in Relation to Cytochrome P450 2D6 Genotype, Age and Smoking Behaviour

J. Ahlner, M. Reis, F. Bengtsson, 2009, Clinical pharmacokinetics.